[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559771":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":44,"responsibleParty":275,"collaborators":33,"id":277,"slug":33,"hasResults":278,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":33,"eligibilityCriteria":282,"healthyVolunteers":278,"sex":283,"minAge":284,"maxAge":33,"enrollmentInfo":285,"targetDuration":33,"studyType":288,"phases":289,"briefSummary":291,"conditions":292,"keywords":300,"overallStatus":47,"whyStopped":33,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},{"fullName":5,"class":6},"Hasten Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HST101(Lerodalcibep)","EXPERIMENTAL","300 mg subcutaneously Q4W",[13],"Drug: Lerodalcibep",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","subcutaneously Q4W",[19],"Drug: matching placebo",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Lerodalcibep","PCSK9 inhibitor",[9],[27,28],"HST101","LIB003",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"matching placebo","placebo",[15],null,[35],{"name":36,"affiliation":37,"role":38},"Yong Huo","Peking University First Hospital","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},"CONTACT","+86 13901333060","huoyong@263.net.cn",[45,62,72,82,92,106,120,134,148,158,172,186,199,212,225,239,253,267],{"facility":46,"status":47,"city":48,"state":49,"zip":33,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Beijing Anzhen Hospital of Capital Medical University","RECRUITING","Beijing","Beijing Municipality","China",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":59,"role":41,"phone":60,"phoneExt":33,"email":61},"Yujie Zhou","+86-10-64412431","azzyj12@163.com",{"facility":63,"status":47,"city":48,"state":49,"zip":33,"country":50,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Beijing Luhe Hospital, Capital Medical Univeristy",{"type":52,"coordinates":65},[54,55],{"lat":55,"lon":54},[68],{"name":69,"role":41,"phone":70,"phoneExt":33,"email":71},"Guangyao Zhai","+86-10-69543901","Drzhaiguangyao@163.com",{"facility":73,"status":47,"city":48,"state":49,"zip":33,"country":50,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"Beijing Tsinghua Changgeng Hospital",{"type":52,"coordinates":75},[54,55],{"lat":55,"lon":54},[78],{"name":79,"role":41,"phone":80,"phoneExt":33,"email":81},"Ping Zhang","+86-10-56112345","zhpdoc@126.com",{"facility":83,"status":47,"city":48,"state":49,"zip":33,"country":50,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"Fuwai Hospital, CAMS & PUMC",{"type":52,"coordinates":85},[54,55],{"lat":55,"lon":54},[88],{"name":89,"role":41,"phone":90,"phoneExt":33,"email":91},"Naqiong Wu","+86-10-88398866","fuwainaqiongwu@163.com",{"facility":93,"status":47,"city":94,"state":95,"zip":33,"country":50,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Guangdong Provincial People's Hospital","Guangzhou","Guangdong",{"type":52,"coordinates":97},[98,99],113.25,23.11667,{"lat":99,"lon":98},[102],{"name":103,"role":41,"phone":104,"phoneExt":33,"email":105},"Ning Tan","+86-20-83827812","tanning100@126.com",{"facility":107,"status":47,"city":108,"state":109,"zip":33,"country":50,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Shijiazhuang People's Hospital","Shijiazhuang","Hebei",{"type":52,"coordinates":111},[112,113],114.47861,38.04139,{"lat":113,"lon":112},[116],{"name":117,"role":41,"phone":118,"phoneExt":33,"email":119},"Jianping Zhang","+86-311-69089999","zjpzjp2013@sina.com",{"facility":121,"status":47,"city":122,"state":123,"zip":33,"country":50,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Daqingshi People's Hospital","Daqing","Heilingjiang",{"type":52,"coordinates":125},[126,127],125,46.58333,{"lat":127,"lon":126},[130],{"name":131,"role":41,"phone":132,"phoneExt":33,"email":133},"Shu Zhang","+86-459-6612000","zhangshu7801182@163.com",{"facility":135,"status":47,"city":136,"state":137,"zip":33,"country":50,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"The 2nd Xiangya Hospital of Central South University","Changsha","Hunan",{"type":52,"coordinates":139},[140,141],112.97087,28.19874,{"lat":141,"lon":140},[144],{"name":145,"role":41,"phone":146,"phoneExt":33,"email":147},"Daoquan Peng","+86-731-85295888","pengdq@hotmail.com",{"facility":149,"status":47,"city":136,"state":137,"zip":33,"country":50,"cosmosGeoPoint":150,"geoPoint":152,"contacts":153},"The Third Xiangya Hospital of Central South University",{"type":52,"coordinates":151},[140,141],{"lat":141,"lon":140},[154],{"name":155,"role":41,"phone":156,"phoneExt":33,"email":157},"Weihong Jiang","+86-731-88618576","jwhxy3@126.com",{"facility":159,"status":47,"city":160,"state":161,"zip":33,"country":50,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Nanchang People's Hospital","Nanchang","Jiangxi",{"type":52,"coordinates":163},[164,165],115.85306,28.68396,{"lat":165,"lon":164},[168],{"name":169,"role":41,"phone":170,"phoneExt":33,"email":171},"Zhaohui Pei","+86-791-86612623","Leak123@126.com",{"facility":173,"status":47,"city":174,"state":175,"zip":33,"country":50,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Binzhou Medical University Hospital","Binzhou","Shandong",{"type":52,"coordinates":177},[178,179],118.01667,37.36667,{"lat":179,"lon":178},[182],{"name":183,"role":41,"phone":184,"phoneExt":33,"email":185},"Huipu Xu","+86-543-3256969","xuhuipu@126.com",{"facility":187,"status":47,"city":188,"state":175,"zip":33,"country":50,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Heze Municipal Hospital","Heze",{"type":52,"coordinates":190},[191,192],115.47358,35.23929,{"lat":192,"lon":191},[195],{"name":196,"role":41,"phone":197,"phoneExt":33,"email":198},"Beijian Chen","+86-530-5613239","cbj9603@163.com",{"facility":200,"status":47,"city":201,"state":175,"zip":33,"country":50,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Qilu Hospital of Shandong University","Jinan",{"type":52,"coordinates":203},[204,205],116.99722,36.66833,{"lat":205,"lon":204},[208],{"name":209,"role":41,"phone":210,"phoneExt":33,"email":211},"Cheng Zhang","+86-531-82166666","zhangc@sdu.edu.cn",{"facility":213,"status":47,"city":214,"state":175,"zip":33,"country":50,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"Zibo Municipal Hospital","Zibo",{"type":52,"coordinates":216},[217,218],118.06333,36.79056,{"lat":218,"lon":217},[221],{"name":222,"role":41,"phone":223,"phoneExt":33,"email":224},"Guanzhong Zheng","+86-533-7162009","m17660292598@163.com",{"facility":226,"status":47,"city":227,"state":228,"zip":33,"country":50,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"West China Hospital of Sichuan University","Chengdu","Sichuan",{"type":52,"coordinates":230},[231,232],104.06667,30.66667,{"lat":232,"lon":231},[235],{"name":236,"role":41,"phone":237,"phoneExt":33,"email":238},"Ye Zhu","+86-28-85422114","zhuye1974@163.com",{"facility":240,"status":47,"city":241,"state":242,"zip":33,"country":50,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Tianjin People's Hospital","Tianjin","Tianjin Municipality",{"type":52,"coordinates":244},[245,246],117.17667,39.14222,{"lat":246,"lon":245},[249],{"name":250,"role":41,"phone":251,"phoneExt":33,"email":252},"Zhuhua Yao","+86-22-87729595","yzhpci@yahoo.com.cn",{"facility":254,"status":47,"city":255,"state":256,"zip":33,"country":50,"cosmosGeoPoint":257,"geoPoint":261,"contacts":262},"The First Affiliated Hospital of Wenzhou Medical Univesity","Wenzhou","Zhejiang",{"type":52,"coordinates":258},[259,260],120.66682,27.99942,{"lat":260,"lon":259},[263],{"name":264,"role":41,"phone":265,"phoneExt":33,"email":266},"Zhouqing Huang","+86-577-55578061","susiehzq@126.com",{"facility":37,"status":268,"city":48,"state":33,"zip":269,"country":50,"cosmosGeoPoint":270,"geoPoint":272,"contacts":273},"NOT_YET_RECRUITING","100034",{"type":52,"coordinates":271},[54,55],{"lat":55,"lon":54},[274],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},{"type":276,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100559771",false,"NCT06568471","A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia","A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia","Inclusion Criteria:\n\n* Provision of written and signed informed consent form prior to any study-specific procedure;\n* Male or female participants ≥18 years of age at the screening visit;\n* Body weight ≥ 40 kg and body mass index (BMI) ≥18 and ≤35 kg\u002Fm2;\n* On a stable diet and lipid-lowering oral drugs (such as statins, ezetimibe or Hybutimibe, omega-3 compounds, fenofibrate, nicotinic acid, etc.) for at least 4 weeks prior to the first drug administration\n* LDL-C≥1.8 mmol\u002FL (70 mg\u002FdL) and TG≤4.52 mmol\u002FL (400 mg\u002FdL) at screening for ASCVD patients or those at very (ultra)-high risk for ASCVD, including patients with HeFH; LDL-C ≥ 2.6 mmol\u002FL (100 mg\u002FdL) and TG ≤ 4.52 mmol\u002FL (400 mg\u002FdL) at screening for patients at high-risk for ASCVD including patients with HeFH;\n* Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a washout period of ≥6 weeks after the last dose; for those on 300 mg or 420 mg Q4W, the washout period is ≥10 weeks following last dose;\n* Female of childbearing potential must have a negative pregnancy test at the last screening visit and consent to use highly effective contraceptives during the trial and 3 months after the last dose of investigational drug.\n\nExclusion Criteria:\n\n* Documented history of homozygous familial hypercholesterolemia (HoFH);\n* Estimated glomerular filtration rate (eGFR)\\\u003C30 mL\u002Fmin\u002F1.73m2;\n* Active liver disease or hepatic dysfunction, history of liver transplant, and\u002For ALT or AST \\>2.5 × ULN at screening;\n* Poorly controlled thyroid disorder including hypothyroidism or hyperthyroidism;\n* Poorly controlled Type 1 or Type 2 diabetes mellitus defined as fasting blood glucose ≥11.0 mmol\u002FL (200 mg\u002FdL) and glycosylated hemoglobin (HbA1c) ≥ 9%;\n* Serious arrhythmia, MI, unstable angina pectoris, PCI, CABG, implantable cardioverter defibrillator, aortic valve surgery or stroke within 3 months prior to the first dose;\n* Planned cardiac surgery or revascularization during the study period;\n* New York Heart Association (NYHA) Class III-IV heart failure;\n* Pregnant or lactating women;\n* Poorly controlled hypertension (SBP≥160 mmHg or DBP≥100 mmHg in a sitting position)\n* Unexplained creatine kinase (CK) \\> 5 x ULN (retested once is needed if suspected to be related to excessive exercise or abnormal activity);\n* LDL apheresis or plasma exchange within 2 months prior to the first dose;\n* HIV, Treponema pallidum, or HCV antibody test positive, or HBV-DNA \\>ULN at screening;\n* History of prescription drug abuse, illicit drug use or alcohol abuse within 6 months prior to screening;\n* History of any major drug allergy, including allergy to protein biologics;\n* Participate another clinical trial within 30 days or less than 5 half-lifes (drug) before screening, whichever is longer","ALL","18 Years",{"count":286,"type":287},210,"ESTIMATED","INTERVENTIONAL",[290],"PHASE3","This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \\[≤31 days\\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high\u002Fhigh risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.",[293,294,295,296,297,298,299],"Hypercholesterolemia","Dyslipidemias","Primary Hypercholesterolemia","Heterozygous Familial Hypercholesterolemia","Hyperlipidemia; Mixed","Metabolic Disease","ASCVD",[24,23,301],"LDL-C","2025-02-04",{"date":304,"type":305},"2025-02-06","ACTUAL",{"date":307,"type":305},"2024-11-16",{"date":309,"type":287},"2026-05",{"name":5,"class":6},18]